TI-CE High-Dose Chemotherapy for Patients With Previously Treated Germ Cell Tumors: Results and Prognostic Factor Analysis
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Purpose: We previously reported a dose-finding and phase II trial of the TI-CE regimen (paclitaxel [T] plus ifosfamide [I] followed by high-dose carboplatin [C] plus etoposide [E] with stem-cell support) in germ cell tumor (GCT) patients predicted to have a poor prognosis with conventional-dose salvage therapy. We now report the efficacy of TI-CE with prognostic factors for disease-free survival (DFS) and overall survival (OS) in our full data set of 107 patients. Patients and Methods: Eligible patients had advanced GCTs with progressive disease following chemotherapy and unfavorable prognostic features (extragonadal primary site, incomplete response [IR] to first-line therapy, or relapse/IR to ifosfamide-cisplatin–based conventional-dose salvage). Univariate and multivariate analyses (MVAs) of prognostic factors were performed. The predictive ability of the Einhorn and Beyer prognostic models was assessed. Results: Most patients were platinum refractory and had an IR to first-line chemotherapy. There were 54 (5%) complete and eight (8%) partial responses with negative markers; 5-year DFS was 47% and OS was 52% (median follow-up, 61 months). No relapses occurred after 2 years. Five (24%) of 21 primary mediastinal nonseminomatous GCTs are continuously disease free. On MVA, primary mediastinal site (P < .001), two or more lines of prior therapy (P < .001), baseline human chorionic gonadotropin ≥ 1,000 U/L (P = .01), and lung metastases (P = .02) significantly predicted adverse DFS. Poor-risk patients did worse than good- or intermediate-risk patients according to both Beyer (P < .002) and Einhorn (P < .05) models. Conclusion: TI-CE is effective salvage therapy for GCT patients with poor prognostic features. Mediastinal primary site and two or more lines of prior therapy were most predictive of adverse DFS. Beyer and Einhorn models can assist in predicting outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., & Thun, M. J. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2007.0010 · Cited by 10,188
(1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.2.594 · Cited by 1,929
High-Dose Chemotherapy and Stem-Cell Rescue for Metastatic Germ-Cell Tumors
Einhorn, L. H., Williams, S. D., Chamness, A., Brames, M. J., Perkins, S. M., & Abonour, R. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067749 · Cited by 496 · cited 10×
“Indiana University abandoned salvage HDCT for PM-NSGCT in the mid-1990s after no durable CRs were achieved among the first 13 patients.(6) Similarly, Beyer et al(11) reported a failure-free survival of only 12% for PM-NSGCT patients undergoing HDCT.”
BackgroundMethodResultInfluentialKondagunta, G. V., Bacik, J., Donadio, A., Bajorin, D., Marion, S., Sheinfeld, J., Bosl, G. J., & Motzer, R. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.19.638 · Cited by 418 · cited 1×
“chemotherapy have a 60% chance of achieving cure with conventional-dose chemotherapy.(4,8) Other patients, such as those with primary refrac-”
BackgroundSelf-citationVinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor.
Loehrer, P. J., Gonin, R., Nichols, C. R., Weathers, T., & Einhorn, L. H. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.7.2500 · Cited by 397
Einhorn, L. H. (1981) · PubMed · Cited by 372
Beyer, J., Kramar, A., Mandanas, R., Linkesch, W., Greinix, A., Droz, J. P., Pico, J. L., Diehl, A., Bokemeyer, C., Schmoll, H. J., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.10.2638 · Cited by 323
Motzer, R. J., Mazumdar, M., Sheinfeld, J., Bajorin, D. F., Macapinlac, H. A., Bains, M., Reich, L., Flombaum, C., Mariani, T., Tong, W. P., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.6.1173 · Cited by 189 · cited 5×
“The safety profile has been previously reported.(15) Fifty-four (50%) patients achieved a CR: 45 (42%) to chemotherapy alone and nine (8%) to chemotherapy plus surgery.”
MethodSelf-citationMotzer, R. J., Agarwal, N., Beard, C. J., Bolger, G. B., Boston, B., Carducci, M. A., Choueiri, T. K., Figlin, R. A., Fishman, M., Hancock, S., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0047 · Cited by 189
Self-citationMotzer, R. J., Geller, N. L., Tan, C. C.-Y., Herr, H., Morse, M., Fair, W., Sheinfeld, J., Sogani, P., Russo, P., & Bosl, G. J. (1991) · Cancer · doi:10.1002/1097-0142(19910301)67:5<1305::aid-cncr2820670506>3.0.co;2-j · Cited by 135
Self-citation
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Gilligan, T., Lin, D. W., Aggarwal, R., Chism, D., Cost, N., Derweesh, I. H., Emamekhoo, H., Feldman, D. R., Geynisman, D. M., Hancock, S. L., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0058 · Cited by 450
Self-citationRajpert-De Meyts, E., McGlynn, K. A., Okamoto, K., Jewett, M. A. S., & Bokemeyer, C. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00991-5 · Cited by 398
Testicular Cancer — Discoveries and Updates
Hanna, N. H., & Einhorn, L. H. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1407550 · Cited by 345
Oldenburg, J., Berney, D. M., Bokemeyer, C., Climent, M. A., Daugaard, G., Gietema, J. A., De Giorgi, U., Haugnes, H. S., Huddart, R. A., Leão, R., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.01.002 · Cited by 235
Adra, N., Einhorn, L. H., Althouse, S. K., Ammakkanavar, N. R., Musapatika, D., Albany, C., Vaughn, D., & Hanna, N. H. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx680 · Cited by 196
“High-dose chemotherapy plus PBSCT achieves cures in 60% of patients with relapsed metastatic GCT [2, 3, 20].”
BackgroundLoh, K. P., & Fung, C. (2017) · Rare Tumors · doi:10.4081/rt.2017.6867 · Cited by 23
Cursano, M. C., Kopf, B., Scarpi, E., Menna, C., Casadei, C., Schepisi, G., Lolli, C., Altavilla, A., Gallà, V., Santini, D., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01325 · Cited by 19
Phase II Trial of Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors
Ashkar, R., Feldman, D. R., Adra, N., Zaid, M. A., Funt, S. A., Althouse, S. K., Perkins, S. M., Snow, C. I., Lazzara, K. M., Sego, L. M., et al. (2021) · Investigational New Drugs · doi:10.1007/s10637-021-01134-1 · Cited by 16
“Salvage chemotherapy can cure up to 50% of patients with relapsed disease when used in the appropriate clinical context [5, 6].”
BackgroundSelf-citation
Metadata
- Authors
- Feldman, D. R., Sheinfeld, J., Bajorin, D. F., Fischer, P., Turkula, S., Ishill, N., Patil, S., Bains, M., Reich, L. M., Bosl, G. J., & Motzer, R. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-04-01
- Volume
- 28
- Issue
- 10
- Pages
- 1706-1713
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2163130660
- Cited by
- 239
- References
- 13
- FWCI
- 10.87
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.